Frequency Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Frequency Therapeutics, Inc.

Frequency Therapeutics, Inc. is a U.S. biotechnology company historically listed on the NASDAQ market under the ticker FREQ and focused on regenerative medicine. The company was incorporated in November 2014 in Delaware and built its operational footprint in the Boston life-sciences cluster, with principal office references in Cambridge, Massachusetts. Its core scientific identity has centered on progenitor cell activation (PCA), a platform designed to stimulate the body’s own progenitor cells in order to repair damaged tissue rather than simply manage symptoms. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1703647/000119312526117883/d42330d424b5.htm?utm_source=openai)) From an operating-history perspective, Frequency Therapeutics was founded by scientists and entrepreneurs associated with the MIT/Harvard ecosystem, with an initial mission to develop regenerative therapies for sensorineural hearing loss and, more broadly, to create disease-modifying treatments for degenerative conditions. That scientific positioning differentiated the company from many biotech peers that rely primarily on traditional small molecules, antibodies, or gene therapies. Its development efforts included FX-322, an investigational candidate aimed at restoring hearing function, alongside additional regenerative programs that reflected the breadth of the platform thesis. ([boston.citybuzz.co](https://boston.citybuzz.co/article/395201/frequency-therapeutics-appoints-marc-a-cohen-as-chairman?utm_source=openai)) In competitive terms, Frequency was positioned as a clinical-stage biotech with a highly differentiated R&D story but also the execution risk typical of early therapeutic platforms. The investment case depended on translating proprietary biology into clinically meaningful outcomes, a hurdle that is particularly challenging in hearing loss and other degenerative diseases. The company also relied on partnerships to extend its reach, including collaboration and development relationships with Astellas Pharma and academic institutions such as MIT, Harvard-linked researchers, and other research organizations. Those relationships helped support credibility, but they did not remove the central binary risk of clinical validation. ([businessabc.net](https://businessabc.net/wiki/frequency-therapeutics?utm_source=openai)) Geographically, the company’s presence was overwhelmingly U.S.-based, anchored in Massachusetts and integrated into one of the world’s strongest biotech innovation hubs. Recent corporate developments are the key point for investors: Frequency Therapeutics announced and subsequently completed a merger with Korro Bio, which changed the company’s standalone profile and effectively repositioned the business within a newly combined corporate structure headquartered in Cambridge, Massachusetts. As a result, Frequency should be viewed less as a pure standalone listed biotech and more as a legacy platform that has been folded into a broader corporate combination. ([ir.korrobio.com](https://ir.korrobio.com/node/6576/pdf?utm_source=openai))